Anti-AMR antibiotics

01Overview and value chain#

Markers EC: REACH | OECD: bio-pharma | Regulator: FDA (USA), NMPA (China), EMA (EU)

New-generation antibiotics mostly work by pairing a beta-lactam core (a cephalosporin or related structure) with a next-generation beta-lactamase inhibitor that blocks the enzymes resistant bacteria use to destroy the antibiotic, or by re-engineering an existing antibiotic class to evade known resistance mechanisms. The field’s economics are notoriously difficult — a novel antibiotic is used sparingly by design (stewardship keeps it in reserve for resistant infections), which caps peak sales far below what the R&D cost would justify — so most of the companies here are small, specialist developers rather than large pharma. 2026 has shown both how far the field has come and how fragile that progress still is: Wockhardt’s zidebactam-cefepime combination (Zaynich) is under FDA fast-track review and EMA accelerated assessment as the first India-developed antibiotic to reach this stage globally, while Venatorx’s cefepime-taniborbactam received an FDA Complete Response Letter over manufacturing data — not efficacy — after its GARDP development partnership had already ended.

The key directions are:

1. Beta-lactam / beta-lactamase-inhibitor combinations: Pairing a cephalosporin with a next-generation inhibitor active against serine- and metallo-beta-lactamases, the resistance enzymes that inactivate older combinations.
2. Re-engineered legacy classes: Modifying an established antibiotic scaffold (tetracyclines, siderophore-conjugated cephalosporins) to restore activity against strains that have evolved resistance to the parent class.
3. Domestic manufacturing resilience: Onshoring API and finished-dose production for a novel antibiotic, treated as a supply-security issue given how concentrated global antibiotic manufacturing has become.
4. Access and stewardship commitments: Structuring pricing and distribution (including for low- and middle-income countries) so a new antibiotic is actually used only where resistance demands it, rather than driving the resistance it was built to fight.

Sectoral value chain#

[Target resistance mechanism ID] ──> [Candidate synthesis & optimization] ──> [Clinical trials vs. resistant pathogens] ──> [Regulatory review]
                                  │
                          (CMC & manufacturing scale-up)
                                  │
                                  ▼
[Stewardship-gated distribution] <─── [Commercial launch] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Metallo-beta-lactamase inhibition: A harder chemistry problem than inhibiting serine beta-lactamases, since metallo-enzymes use a different catalytic mechanism — several of this decade’s candidates are built specifically to close this gap.
• Siderophore-conjugation: Attaching an antibiotic to an iron-chelating siderophore so bacteria’s own iron-uptake channels pull the drug across their outer membrane, the mechanism behind Shionogi’s cefiderocol.
• CMC-first development: Building out commercial-scale, ideally domestic, manufacturing capability in parallel with clinical development rather than after approval, in response to well-publicized antibiotic supply-chain fragility.

02US#

The United States hosts the field’s most commercially established players alongside a cautionary example of how a regulatory-manufacturing gap, not a scientific failure, can stall an otherwise sound candidate.

Domestic manufacturing, fast-track pathways, a CRL over CMC not efficacy#

• Paratek Pharmaceuticals: NUZYRA (omadacycline), a next-generation tetracycline active against Gram-positive, Gram-negative and atypical pathogens, completed U.S. onshoring of its supply chain in 2024, making it, by the company’s account, the only novel antibiotic with fully domestic U.S. manufacturing — a direct response to supply-security concerns rather than a clinical claim.
• Innoviva: XACDURO (sulbactam-durlobactam), marketed through its Innoviva Specialty Therapeutics subsidiary and FDA-approved in 2023 for Acinetobacter infections, is one of the few genuinely new mechanisms to reach the U.S. market this decade.
• Venatorx Pharmaceuticals: cefepime-taniborbactam, designed to cover metallo-beta-lactamase-producing pathogens that most existing combinations miss, received an FDA Complete Response Letter requesting additional chemistry-manufacturing-controls data — the FDA did not raise safety or efficacy concerns — after its GARDP co-development partnership had already been terminated, leaving the manufacturing gap unfunded by that partner.

03CN#

China’s novel-antibiotic pipeline is still shallow relative to its manufacturing scale, with the clearest 2026 signal being a foreign originator’s regulatory filing rather than a homegrown commercial launch.

NMPA filing for an imported originator, a thin domestic pipeline#

• Shionogi’s cefiderocol NDA: Shionogi’s New Drug Application for cefiderocol (Fetroja) was accepted by the NMPA in August 2024, extending an already-approved (Japan, US) siderophore-cephalosporin into the Chinese market rather than reflecting a domestic Chinese discovery.
• Domestic pipeline scale: Published reviews of China’s antibacterial clinical pipeline count roughly 18 agents in active development (one under regulatory review, five in Phase 3, six in Phase 2, six in Phase 1) as of the most recent published count — a real and growing pipeline, but still dominated by re-engineered legacy classes rather than genuinely new mechanisms comparable to Venatorx’s or Wockhardt’s candidates.
• No China-headquartered company with a novel antibiotic at or near approval matching the US/EU candidates in this table was confirmed — a genuine pipeline-maturity gap rather than a coverage gap.

04EU#

Europe combines a leading novel beta-lactam-combination candidate with a structural funding problem that has already claimed one high-profile partnership this year.

Accelerated assessment pathways, a terminated GARDP partnership, oral-BLI ambitions#

• Wockhardt’s EMA filing: the same zidebactam-cefepime combination under FDA fast-track review was granted Accelerated Assessment eligibility by the EMA in January 2026 for complicated UTI including pyelonephritis, reflecting the EU regulator’s own read on unmet medical need in MDR Gram-negative infection.
• Mutabilis: developing what it describes as a potential first novel oral beta-lactam/beta-lactamase-inhibitor combination since amoxicillin-clavulanate (Augmentin) in 1981, targeting complicated UTI and pyelonephritis caused by E. coli — still in clinical development, not yet at the regulatory-filing stage its EU and US peers in this table have reached.
• GARDP partnership termination: the ending of the GARDP-Venatorx collaboration on cefepime-taniborbactam is a concrete illustration of the field’s funding fragility — a not-for-profit AMR-focused partnership exiting mid-program removes exactly the kind of support meant to de-risk the manufacturing and access work that antibiotic economics otherwise can’t fund on their own.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack centers on two hard chemistry problems — inhibiting the enzymes that inactivate beta-lactams, and getting a drug across a Gram-negative bacterium’s outer membrane at all — plus the CMC and stewardship infrastructure that decides whether a scientifically sound candidate actually reaches patients.

1. Metallo-Beta-Lactamase Inhibition:
   • Boronic-acid-based inhibitors (the taniborbactam class) are designed to cover metallo-beta-lactamases, which use a zinc-dependent mechanism that most first-generation inhibitors (built for serine enzymes) cannot touch.
2. Beta-Lactam Enhancer Mechanisms:
   • Wockhardt’s zidebactam acts as a “beta-lactam enhancer,” binding penicillin-binding protein 2 to trigger bacterial cell death independent of the classic beta-lactamase-inhibition route, intended to stay active even against some carbapenem-resistant strains.
3. Siderophore-Mediated Uptake:
   • Cefiderocol is conjugated to a catechol siderophore, exploiting the iron-starved bacterium’s own TonB-dependent iron transporters to actively pull the drug across the outer membrane rather than relying on passive porin diffusion.

07Value chains and production pipelines#

Industrial pipeline of a novel beta-lactam/BLI combination (Commercial Launch)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. API synthesis           │ ───> │ 2. Combination formulation │
│    (beta-lactam + inhibitor)│      │    & fixed-dose ratio      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Clinical + CMC dossier │ <─── │ 3. GMP sterile fill-finish │
│    assembly                │      │    (IV formulation)        │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Regulatory review       │ ───> │ 6. Stewardship-gated       │
│    (FDA/EMA/NMPA)          │      │    hospital distribution   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: API synthesis

The beta-lactam core and the inhibitor molecule are synthesized as separate active pharmaceutical ingredients, each requiring its own multi-step organic synthesis and purity specification.

Stage 2: Combination formulation and fixed-dose ratio

The two APIs are combined at a defined ratio (for example, cefepime 2g / zidebactam 1g) established from pharmacokinetic/pharmacodynamic modeling against the target resistant pathogens.

Stage 3: GMP sterile fill-finish

Most candidates in this table are IV formulations for hospitalized patients with serious infections, requiring aseptic fill under GMP conditions rather than oral solid-dose manufacturing.

Stage 4: Clinical and CMC dossier assembly

Efficacy/safety data from trials enrolling drug-resistant infections is assembled alongside the full chemistry-manufacturing-controls package — the CMC package specifically is where Venatorx’s candidate stalled despite clean clinical data.

Stage 5: Regulatory review

FDA, EMA and NMPA review, increasingly through accelerated or fast-track designations reflecting AMR’s public-health priority status, though a CMC gap can still trigger a Complete Response Letter regardless of the pathway.

Stage 6: Stewardship-gated hospital distribution

Approved product is distributed through hospital formularies with stewardship restrictions that reserve it for confirmed or strongly suspected resistant infections, deliberately capping volume to preserve the drug’s effectiveness for as long as possible.